

1 **The citrate transporter SLC13A5 as a therapeutic target for kidney disease:**
2 **evidence from Mendelian randomization to inform drug development**

3

4 Dipender Gill BMBCh PhD^{1,2}, Loukas Zagkos PhD¹, Rubinder Gill MSc², Thomas Benzing
5 MD^{3,4}, Jens Jordan MD^{5,6}, Andreas L. Birkenfeld MD⁷⁻⁹, Stephen Burgess PhD¹⁰, Grit Zahn
6 PhD¹¹

7

- 8 1. Department of Epidemiology and Biostatistics, School of Public Health, Imperial College
9 London, London, United Kingdom.
- 10 2. Primula Group Ltd, London, United Kingdom.
- 11 3. Department II of Internal Medicine and Center for Molecular Medicine Cologne (CMMC),
12 University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne,
13 Germany.
- 14 4. Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases
15 (CECAD), University of Cologne, Germany.
- 16 5. Institute of Aerospace Medicine, German Aerospace Center (DLR), Cologne, Germany.
- 17 6. Medical Faculty, University of Cologne, Cologne, Germany.
- 18 7. Department of Diabetology Endocrinology and Nephrology, Internal Medicine IV, University
19 Hospital Tübingen, Eberhard Karls University Tübingen, Tübingen, Germany.
- 20 8. Division of Translational Diabetology, Institute of Diabetes Research and Metabolic Diseases
21 (IDM) of the Helmholtz Center Munich, Eberhard Karls University Tübingen, Tübingen,
22 Germany, a partner of the German Center for Diabetes Research (DZD e.V.).
- 23 9. Department of Diabetes, School of Life Course Science and Medicine, King's College London,
24 London, United Kingdom.
- 25 10. Medical Research Council Biostatistics Unit at the University of Cambridge, Cambridge,
26 United Kingdom.
- 27 11. Eternygen GmbH, Berlin, Germany.

28

29 **Corresponding author details:**

30 Dr Dipender Gill

31 Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London,
32 London, United Kingdom

33 Telephone: +44 7904843810

34 E-mail: dipender.gill@imperial.ac.uk

35

36

37 **Manuscript word count: 3,408**

38 **Abstract** (386 words)

39 Background: Solute carrier family 13 member 5 (SLC13A5) is a Na⁺-coupled citrate co-transporter
40 that mediates the entry of extracellular citrate into the cytosol. SLC13A5 inhibition has been
41 proposed as a therapeutic target for reducing progression of kidney disease via its effects on citrate
42 metabolism. However, evidence of its efficacy in humans is limited. The aim of this study was to
43 leverage the Mendelian randomization paradigm to gain insight into the effects of SLC13A5 inhibition
44 in humans, towards prioritizing and informing clinical development efforts.

45 Methods: The primary Mendelian randomization analyses investigated the effect of SLC13A5
46 inhibition on measures of kidney function, including creatinine and cystatin C based measures of
47 estimated glomerular filtration rate (creatinine-eGFR and cystatin C-eGFR), blood urea nitrogen
48 (BUN), urine albumin-creatinine ratio (uACR), and risk of chronic kidney disease and
49 microalbuminuria. Secondary analyses included a paired plasma and urine metabolome-wide
50 association study, investigation of secondary traits related to SLC13A5 biology, a phenome-wide
51 association study (PheWAS), and a proteome-wide association study. All analyses were compared to
52 the effect of genetically predicted plasma citrate levels using variants selected from across the
53 genome, and statistical sensitivity analyses robust to the inclusion of pleiotropic variants were also
54 performed. Data were obtained from large scale genetic consortia and biobanks, with sample sizes
55 ranging from 5,023 to 1,320,016 individuals.

56 Results: We found evidence of associations between genetically proxied SLC13A5 inhibition and
57 higher creatinine-eGFR ($p=0.002$), cystatin C-eGFR ($p=0.005$), and lower BUN ($p=3\times 10^{-3}$). Statistical
58 sensitivity analyses robust to the inclusion of pleiotropic variants suggested that these effects may be
59 a consequence of higher plasma citrate levels. There was no strong evidence of associations of
60 genetically proxied SLC13A5 inhibition with uACR or risk of CKD or microalbuminuria. Secondary
61 analyses also identified evidence of associations with higher plasma calcium levels ($p=6\times 10^{-13}$) and
62 lower fasting glucose ($p=0.02$). PheWAS did not identify any safety concerns.

63 Conclusion: This Mendelian randomization analysis provides human-centric insight to guide clinical
64 development of an SLC13A5 inhibitor. We identify plasma calcium and citrate as biologically plausible
65 biomarkers of target engagement, and plasma citrate as a potential biomarker of mechanism of
66 action. Our human genetic evidence corroborates evidence from various animal models to support
67 effects of SLC13A5 inhibition on improving kidney function. Further study in the form of early-stage
68 clinical trials may now be warranted to help translate these findings towards improving patient care.

69

70 **Key words**

71 SLC13A5, citrate, kidney, renal function, Mendelian randomization, drug development

72 **Acronyms**

73 BUN: blood urea nitrogen

74 CI: confidence interval

75 CKD: chronic kidney disease

76 CRP: c-reactive protein

77 eGFR: estimated glomerular filtration rate

78 FDR: false-discovery rate

79 GWAS: genome-wide association study

80 HDLc: high-density lipoprotein cholesterol

81 IL6: interleukin-6

82 IVW: inverse-variance weighted

83 LDLc: low-density lipoprotein cholesterol

84 OR: odds ratio

85 PheWAS: phenome-wide association study

86 SD: standard deviation

87 SNP: single-nucleotide polymorphism

88 uACR: urine albumin-creatinine ratio

89 Introduction

90 The kidney is a highly metabolically active organ. The provision of citric acid cycle intermediates has
91 ameliorated renal tubular damage and progression of chronic renal injury in animal models [1–3].
92 Solute carrier family 13 member 5 (SLC13A5), which is primarily expressed in hepatocytes of the liver,
93 is a membrane-bound Na⁺-coupled co-transporter responsible for moving extracellular citrate into
94 the cytosol [4,5]. Systemic SLC13A5 inhibition could augment citrate flux to the kidney, thereby
95 supporting renal energy metabolism. Moreover, given the role of citrate in regulating glucose
96 metabolism, lipid metabolism, and inflammation, SLC13A5 inhibition could indirectly affect renal
97 health [6–13]. However, no SLC13A5 inhibitor has yet entered clinical study, and so evidence of its
98 efficacy for ameliorating progression of kidney disease in humans is limited. Additionally, SLC13A5
99 shows species-specific effects [11,14–16].

100 Insights from human genetic data offer a powerful opportunity to prioritize and inform the design of
101 clinical research. Given that learnings from such genetic analyses relate to the target organism,
102 namely humans, they are well-placed to overcome some of the limitations of translating findings
103 from animal models [17]. As genes code for proteins and proteins make up the majority of drug
104 targets, it follows that naturally occurring variation in the genes coding for drug target proteins can
105 be leveraged to inform on the effect of their pharmacological perturbation [18]. The random
106 allocation of genetic variants at conception means that their association with clinical traits and
107 phenotypes are less susceptible to the confounding factors and reverse causation bias that can
108 hinder causal inference in traditional epidemiological study designs. The current availability of
109 publicly accessible large-scale genetic association data also means that such a drug-target Mendelian
110 randomization paradigm is a relatively fast and cost-effective approach for inferring the potential
111 clinical effects of perturbing drug targets [19].

112 Given the pre-clinical evidence supporting potential therapeutic applications of SLC13A5 inhibition
113 [10,12,13,20,21], we sought to investigate its effects using drug target Mendelian randomization. By
114 utilizing the known effect of SLC13A5 inhibition on increasing plasma citrate levels to identify genetic
115 instruments [10,22,23], our primary objective was to investigate its effects on parameters of kidney
116 function. In secondary analyses, we aimed to unravel potential mechanisms of action, as well as
117 evidence of broader effects on glucose and lipid metabolism, and inflammation. Such insights would
118 thus serve to inform and prioritize clinical development efforts for SLC13A5 inhibitors.

119 **Methods**

120 ***Study design overview***

121 Genetic instruments for SLC13A5 inhibition were first identified as minimally correlated ($r^2 < 0.1$)
122 single-nucleotide polymorphisms (SNPs) within 200kB of the *SLC13A5* gene (chromosome 17, base
123 position 6,588,032 to 6,616,886 on reference panel GRCh37/hg19 by Ensembl) that associate with
124 plasma citrate levels at a genome-wide significance level ($p < 5 \times 10^{-8}$). Instrument validity was affirmed
125 by performing Mendelian randomization to explore associations with plasma calcium levels, whose
126 levels are postulated to be increased with SLC13A5 inhibition due to reduced sequestration in the
127 bone [24]. Such an association would also support plasma calcium as a biomarker of target
128 engagement for SLC13A5 inhibition.

129 Primary Mendelian randomization analyses were then performed to investigate the association of
130 genetically proxied SLC13A5 inhibition with creatinine and cystatin C based measures of estimated
131 glomerular filtration rate (eGFR), blood urea nitrogen (BUN), urine albumin-creatinine-ratio (uACR),
132 and risk of microalbuminuria and chronic kidney disease (CKD).

133 To investigate whether any effect of SLC13A5 inhibition on parameters of kidney function may be
134 attributable to metabolic effects in the plasma that consequently affect kidney function,
135 metabolome-wide Mendelian randomization of the plasma and urine was undertaken for SLC13A5
136 inhibition. Evidence of concordant effects of SLC13A5 inhibition on biomarkers measured in the
137 plasma and urine would be consistent with metabolic effects resulting in compensatory mechanisms
138 in the kidney, whereas evidence of contrasting effects in the plasma and urine would suggest a
139 process specific to the kidney underlying the effects.

140 Secondary Mendelian randomization analyses were performed to explore the human genetic
141 evidence for effects of SLC13A5 inhibition on biomarkers of glucose and lipid metabolism, and
142 inflammation, namely plasma low-density lipoprotein cholesterol (LDLc), high-density lipoprotein
143 cholesterol (HDLc), triglycerides, fasting glucose, interleukin 6 (IL6) and C-reactive protein (CRP).
144 Finally, given that SLC13A5 is predominantly expressed in the liver and is involved in glucose and lipid
145 metabolism [10,12,20,25], we also investigated potential effects on liver fat.

146 In order to gain potential insight into mediating mechanisms and pathways implicated in the effects
147 of SLC13A5 inhibition, we also performed a proteome-wide Mendelian randomization study. Finally,
148 to investigate potential on-target adverse effects or novel indications, we performed a phenome-
149 wide association study (PheWAS) [26].

150 To explore whether plasma citrate is a potential mediating mechanism for any associations identified,
151 and thus could serve as a biomarker of mechanism of action, all analyses that considered genetically
152 proxied SLC13A5 as the exposure were also repeated for genetically predicted plasma citrate levels,
153 by selecting instruments from throughout the genome rather than confined to the *SLC13A5* gene
154 region.

155 A schematic figure depicting the overall study design is presented in Figure 1.

156

157 ***Statistical analysis***

158 ***Instrument strength***

159 Instrument strength was estimated by calculating the F-statistic for each SNP using the chi-squared
160 approximation, which for each variant is the square of the SNP-exposure association estimate
161 divided by the square of the SNP-exposure association estimate's standard error [27].

162

163 *Mendelian randomization*

164 The genome-wide association study summary data sources used for the Mendelian randomization
165 analyses are presented in Table 1 [28–38]. Participant consent and ethical approval for all data were
166 obtained in the original studies.

167 The main Mendelian randomization analyses were performed using the random-effects inverse-
168 variance weighted (IVW) method [39]. This meta-analyses the Wald ratio estimates for each
169 instrument SNP using a random-effects inverse-variance model. After harmonising SNPs by their
170 effect alleles, the Wald ratio estimate is calculated by dividing the SNP-exposure association estimate
171 by the SNP-outcome association estimate. The standard error of the Wald ratio estimate was
172 calculated using the propagation of error method.

173 Two Mendelian randomization statistical sensitivity analyses were employed, Egger and weighted
174 median, which make distinct assumptions regarding the inclusion of pleiotropic variants. The Egger
175 method regresses the SNP-outcome association estimates on the SNP-exposure association
176 estimates [40]. The slope of the regression provides a Mendelian randomization estimate that is
177 corrected for pleiotropic associations of the genetic variants and the intercept serves as a test for the
178 presence of such pleiotropic associations, provided that the magnitudes of these pleiotropic
179 associations are not correlated to instrument strength. The weighted median method orders the
180 Wald ratio estimates for all instrument SNPs weighted by their precision, and selects the median
181 value, with 95% confidence intervals (95% CIs) calculated by bootstrapping [41]. It provides an
182 accurate Mendelian randomization estimate when more than half the information for the analysis
183 comes from valid instruments. Heterogeneity in MR estimates derived from individual SNPs can also
184 signify the presence of potential bias from pleiotropy and was assessed using the Cochran's Q test
185 [42]. All Mendelian randomization analyses were performed using the "MendelianRandomization"
186 package for R statistical software [43].

187

188 *Phenome-wide association study*

189 PheWAS was performed in the UK Biobank, a prospective cohort study initiated in 2006 that
190 recruited more than 500,000 participants aged between 40 and 69 years [44]. Participants
191 contributed phenotypic and genetic data, as well as biological samples, as previously reported [45].
192 UK Biobank has approval from the North West Multi-centre Research Ethics Committee and all
193 participants provided appropriate consent.

194 PheWAS statistical analysis was performed by first constructing a weighted genetic risk score for the
195 exposure using the same instrument SNPs as employed in the Mendelian randomization analysis. For
196 each individual included in the analysis, the number of plasma citrate-increasing alleles for each
197 instrument SNP were multiplied by the corresponding genetic association estimate with citrate for
198 that SNP, before combining by addition. International Classification of Diseases versions 9 and 10
199 were used to ascertain cases in the UK Biobank Hospital Episode Statistics data, with diagnoses
200 linked to the phenotype code (phecode) grouping system to facilitate classification of clinically
201 relevant traits [46]. Logistic regression was performed for each phecode against the standardized

202 genetic risk score for the exposure, adjusting for age, sex, and the first 10 genetic principal
203 components of genetic ancestry. Only phecodes with 200 or more cases were included in the
204 analysis, to avoid inclusion of outcomes with low statistical power. PheWAS estimates are reported
205 per 1-SD higher standardized exposure genetic risk score. PheWAS was conducted using the
206 “PheWAS” package of R statistical software [47].

207

208 *Statistical significance ascertainment*

209 To account for testing of multiple outcomes in the primary Mendelian randomization analysis of
210 renal outcomes, the Benjamini–Hochberg false discovery rate (FDR) 5% threshold was used. No
211 statistical significance threshold was used for the other analyses, which were exploratory in nature.
212 All presented p-values are uncorrected for multiple testing, unless otherwise stated.

213

214 *Comparison of SLC13A5 inhibition with higher plasma citrate levels by any mechanism*

215 The Mendelian randomization and PheWAS analyses were also performed considering the exposure
216 of plasma citrate levels, rather than SLC13A5 inhibition. Selection of genetic variants to serve as
217 instruments and build the weighted genetic risk score for plasma citrate was undertaken using the
218 same approach as for SLC13A5 inhibition, except that selection of variants was not confined to the
219 *SLC13A5* gene region.

220

221 *Correlation between plasma and urine metabolome-wide Mendelian randomization results*

222 To measure the correlation between the plasma and urine metabolome-wide Mendelian
223 randomization z-score results, comparison was restricted to all those metabolites analysed in both
224 plasma and urine, and associated with genetically proxied SLC13A5 inhibition at FDR $p < 0.2$ in either
225 analysis.

226

227 *Availability of code and data*

228 R statistical software was used for all analyses. The statistical code used in this work is available upon
229 reasonable request to the corresponding author. All genome-wide association study summary data
230 are publicly available from the sources cited in Table 1. UK Biobank individual participant data are
231 available upon appropriate application to the UK Biobank study. This work was reported using the
232 “Strengthening the Reporting of Observational Studies in Epidemiology using Mendelian
233 Randomization” (STROBE-MR) checklist (Supplementary checklist) [48].

234 Results

235 A total of 13 SNPs were identified as instruments for SLC13A5 inhibition (Supplementary Table 1), all
236 of which had F-statistics > 10, consistent with low risk of weak instrument bias that might affect the
237 conclusions of Mendelian randomization analyses.

238 The main IVW Mendelian randomization identified positive associations of genetically proxied
239 SLC13A5 inhibition with plasma calcium levels. Every 1-SD higher genetically proxied plasma citrate
240 through SLC13A5 inhibition was associated with a 0.132 SD units higher plasma calcium level (95% CI
241 0.107 to 0.157, $p=6 \times 10^{-13}$).

242 Figure 2 depicts the associations of genetically proxied SLC13A5 inhibition with kidney function
243 parameters from the main IVW Mendelian randomization analysis. There were statistically significant
244 associations of genetically proxied SLC13A5 inhibition with higher creatinine and cystatin C based
245 measures of eGFR (FDR adjusted p values = 0.006 and 0.01 respectively), and lower BUN (FDR
246 adjusted p value = 0.002). There were no strong associations of genetically proxied SLC13A5
247 inhibition with uACR (FDR adjusted p value = 0.682), or risk of CKD (FDR adjusted p value = 0.516) or
248 microalbuminuria (FDR adjusted p value = 0.682).

249 The results of the metabolome-wide Mendelian randomization analysis investigating the effects of
250 SLC13A5 inhibition on plasma and urine metabolites are presented in Supplementary Tables 2 and 3.
251 For the 7 metabolites present in both analyses and associated with genetically proxied SLC13A5
252 inhibition at FDR $p < 0.2$ in either analysis (citrate, aconitate, acetylspermidine, alpha-
253 hydroxyisocaproate, propyl 4-hydroxybenzoate sulfate, (2-butoxyethoxy)acetic acid, 8-
254 methoxykynurenate), the correlation coefficient of their z-scores in the analysis of plasma and urine
255 was 0.78 ($p=0.04$).

256 The main IVW Mendelian randomization analysis results measuring the association of genetically
257 proxied SLC13A5 inhibition with parameters of glucose and lipid metabolism, and inflammation are
258 presented in Figure 3. In this hypothesis-generating analysis, there were no significant associations
259 after adjusting for multiple testing, but some evidence to support possible associations of SLC13A5
260 inhibition with lower fasting glucose levels (-0.026 mmol/l per 1-SD higher plasma citrate through
261 SCL13A5 inhibition, 95% CI -0.047 to 0.004, raw $p=0.022$). Neither proteome-wide Mendelian
262 randomization (Supplementary Table 4) nor PheWAS (Supplementary Table 5) identified any
263 significant associations for genetically proxied SLC13A5 inhibition after correcting for multiple
264 testing.

265 All analyses were also performed considering higher plasma citrate through any mechanism as the
266 exposure, instead of genetically proxied SLC13A5 inhibition (i.e., SNPs associated with higher plasma
267 citrate selected as in the analysis for SLC13A5, but not restricted to 200kB within the *SLC13A5* gene).
268 The SNPs used as instruments for plasma citrate are presented in Supplementary Table 6, and the
269 analysis results are presented in Supplementary Tables 7-10. Although the main IVW analysis did not
270 identify evidence supporting associations of genetically predicted plasma citrate levels with eGFR or
271 BUN, the Egger and weighted median sensitivity analyses that are more robust to the inclusion of
272 pleiotropic SNPs were more supportive of such an association (Supplementary Table 11). This
273 suggests that the genetic variants that affect plasma citrate are heterogeneous in the mechanisms by
274 which they achieve this, and consistent with this, there was strong evidence of heterogeneity in all
275 the IVW MR analyses undertaken with plasma citrate as the exposure (Supplementary Table 11).

276 Discussion

277 Using large-scale genetic association data, we identified a genetic instrument for SLC13A5 inhibition
278 that we leveraged in the Mendelian randomization paradigm to provide clinically translatable
279 insights. Our main findings generated human genetic evidence that supports higher plasma citrate
280 and calcium as biologically plausible biomarkers of target engagement, higher plasma citrate as a
281 potential mechanism of action, and favourable effects on parameters of kidney function, namely
282 creatinine and cystatin C based measures of eGFR, and BUN. Of note, we did not identify statistically
283 significant evidence of effects of SLC13A5 inhibition on uACR nor risk of microalbuminuria. This
284 discrepancy may be explained by these biomarkers measuring different domains of kidney function
285 [49]. Of relevance, calcium citrate treatment in an acute kidney damage animal model resulted in
286 significantly reduced levels of proteinuria [1]. The primary Mendelian randomization analysis also did
287 not identify evidence of SLC13A5 inhibition having effects on CKD risk, which may in part be
288 explained by the pathophysiological heterogeneity underlying CKD [50], and SLC13A5 inhibition
289 potentially only being relevant to some of these mechanisms.

290 The correlation between the associations of genetically proxied SLC13A5 with the plasma and urine
291 metabolomes is consistent with effects of SLC13A5 on the urine being downstream to effects on the
292 plasma, and the kidney compensating plasma changes through altered renal excretion. This would
293 also support that effects of SLC13A5 inhibition on kidney function may be occurring through
294 metabolic effects originating outside the kidney. Secondary Mendelian randomization analyses
295 supported potential effects of SLC13A5 inhibition on reducing fasting glucose. Given that SLC13A5 is
296 predominantly expressed in the liver [25], these findings are consistent with direct hepatic effects.
297 The lack of strong associations of genetically proxied SLC13A5 inhibition with clinical outcomes in
298 PheWAS is reassuring regarding safety profile. This suggests smaller reductions in SLC13A5 activity
299 are unlikely to recapitulate the autosomal-recessive epileptic encephalopathy phenotype observed
300 with rare mutations affecting critical regions of the *SLC13A5* gene [51].

301 SLC13A5 is a membrane-bound citrate transporter, and its inhibition results in reduced entry of
302 plasma citrate into the cytosol [4,5]. This would be expected to have implications for cellular
303 metabolism in cells expressing SLC13A5, with the higher circulating plasma citrate levels also
304 potentially impacting metabolism systemically. Consistent with the results of our main genetic
305 analyses, previous work has identified protective effects of citrate in various animal models of kidney
306 disease [1,6,52,53]. Although the main IVW Mendelian randomization analysis investigating effects
307 of plasma citrate levels did not identify evidence supporting effects on parameters of kidney
308 function, there was strong evidence of heterogeneity in estimates generated by individual SNPs,
309 consistent with the presence of pleiotropic effects that could bias the main IVW analyses [42].
310 Furthermore, the Egger and weighted median Mendelian randomization statistical sensitivity
311 analyses, which can be more robust to the inclusion of pleiotropic variants, produced estimates more
312 suggestive of favourable effects of higher plasma citrate on measures of kidney function. This
313 observation may suggest that plasma citrate is a heterogeneous trait that is affected through several
314 distinct pathways, and that at least some of these may favourably impact kidney function. This would
315 be in-keeping with the favourable effects of SLC13A5 on kidney function occurring through its effects
316 on plasma citrate. It has been reported that low citrate levels in urine are associated with various
317 forms of kidney disease, and low urinary citrate is a biomarker for kidney disease progression [52,54–
318 59]. Furthermore, preclinical studies with SLC13A5 knockout mice have supported effects on
319 sympathoadrenal mechanisms [60], which may also contribute to nephroprotective effects of
320 genetically proxied SLC13A5 inhibition.

321 There are several hypotheses for how citrate may exert its beneficial effects on kidney function.
322 Generally, elevated plasma citrate levels are proposed to lead to increased excretion of citrate
323 through the urine. Higher urinary citrate may in turn provide an additional energy supply for kidney
324 cells, potentially enhancing their resilience and function. Furthermore, citrate may contribute to
325 supporting the biosynthesis of essential molecules such as glucose, lipids, and amino acids.
326 Additionally, it is known, due to its alkalinizing function citrate contributes to improved acid-base
327 balance within the kidneys, promoting a favourable environment for cellular processes. Finally,
328 urinary citrate's solubilizing properties might offer protection against vascular calcification and the
329 formation of kidney stones, thus safeguarding kidney health.

330 This work has several strengths. By leveraging large-scale genetic association data within the
331 Mendelian randomization paradigm, we were able to rapidly perform several hypothesis-driven and
332 hypothesis-free genetic analyses relevant to humans, and consequently generate insight related to
333 drug development. Our findings represent numerous potential learnings, including highlighting
334 higher plasma citrate and calcium as a biomarker of target engagement, higher plasma citrate as a
335 biomarker of mechanism of action, efficacy for reducing progression of kidney disease, general safety
336 profile, and potential effects on reducing fasting glucose. Further, the random allocation of genetic
337 variants at conception means that these findings are less vulnerable to the confounding and reverse
338 causation bias that can hinder causal inference in traditional epidemiological study designs [61].

339 This work should also be interpreted in the context of its limitations. The Mendelian randomization
340 paradigm considers small lifelong effects of germline genetic variation. This is not the same as a
341 discrete clinical intervention in later life, which may be of shorter duration but larger magnitude.
342 Thus, it is possible that some of the findings of these genetic analyses may not predict what is
343 observed with inhibition of SLC13A5 in clinical practice, particularly in quantitative terms. Further,
344 some of our current analyses may also be limited by phenotypic definition and statistical power.
345 While challenges in estimating the variance of drug target perturbation predicted by genetic variants
346 means that it is not possible to perform conventional power calculations for drug target Mendelian
347 randomization [62], some indication of the relative statistical power available for each analysis is
348 apparent from the size of the 95% CIs. From this, it is clear that the analyses considering CKD had
349 much less power than those considering measures of eGFR or BUN, for example. Of relevance,
350 numerous preclinical mechanistic studies have demonstrated a role of SLC13A5 in favourably
351 affecting hepatic lipid and glucose metabolism [10–13,20,21,63,64], and the limitations of our
352 current analyses may explain the discrepancy in findings. The plasma and urine metabolome-wide
353 Mendelian randomization analyses were undertaken using outcome data obtained from a CKD
354 population and may thus be vulnerable to collider bias [65]. This is because stratifying on a collider
355 can introduce associations with confounding factors. Our Mendelian randomization evidence
356 supports effects of SLC13A5 inhibition on parameters of kidney function, in-keeping with CKD
357 therefore representing a potential collider. While there are strategies available to help explore
358 potential bias from this [66], they either require individual participant data, which were not available
359 for the current Mendelian randomization analyses, or have other prohibitive limitations [67]. Finally,
360 the genetic analyses undertaken in this work provide insight into the on-target effects of perturbing
361 SLC13A5 [19], but cannot directly inform on the effects of any pharmacological agents used to inhibit
362 SLC13A5, including their pharmacokinetic and pharmacodynamic properties, or off-target effects.

363 In summary, this Mendelian randomization analysis provides novel human-centric insight to guide
364 the clinical development of an SLC13A5 inhibitor. We identify biologically plausible biomarkers of
365 target engagement and mode of action, as well as genetic evidence supporting potential effects in
366 improving kidney function, with higher plasma citrate levels a possible underlying mechanism. The

367 null PheWAS findings are reassuring in that they do not identify any safety signals. Further study in
368 the form of early-stage clinical trials may now be warranted to help translate these findings towards
369 improving patient care.

370 References

- 371 [1] Gadola L, Noboa O, Marquez MN, Rodriguez MJ, Nin N, Boggia J, et al. Calcium citrate
372 ameliorates the progression of chronic renal injury. *Kidney Int* 2004;65.
373 <https://doi.org/10.1111/j.1523-1755.2004.00496.x>.
- 374 [2] Weinberg JM, Venkatachalam MA, Roeser NF, Saikumar P, Dong Z, Senter RA, et al. Anaerobic
375 and aerobic pathways for salvage of proximal tubules from hypoxia-induced mitochondrial
376 injury. *Am J Physiol Renal Physiol* 2000;279.
377 <https://doi.org/10.1152/ajprenal.2000.279.5.f927>.
- 378 [3] Feldkamp T, Kribben A, Roeser NF, Senter RA, Weinberg JM. Accumulation of nonesterified
379 fatty acids causes the sustained energetic deficit in kidney proximal tubules after hypoxia-
380 reoxygenation. *Am J Physiol Renal Physiol* 2006;290.
381 <https://doi.org/10.1152/ajprenal.00305.2005>.
- 382 [4] Zhang L, Hu W, Qiu Z, Li Z, Bian J. Opportunities and Challenges for Inhibitors Targeting Citrate
383 Transport and Metabolism in Drug Discovery. *J Med Chem* 2023.
384 <https://doi.org/10.1021/acs.jmedchem.3c00179>.
- 385 [5] Inoue K, Zhuang L, Maddox DM, Smith SB, Ganapathy V. Human sodium-coupled citrate
386 transporter, the orthologue of *Drosophila* Indy, as a novel target for lithium action.
387 *Biochemical Journal* 2003;374. <https://doi.org/10.1042/BJ20030827>.
- 388 [6] Bienholz A, Reis J, Sanli P, De Groot H, Petrat F, Guberina H, et al. Citrate shows protective
389 effects on cardiovascular and renal function in ischemia-induced acute kidney injury. *BMC*
390 *Nephrol* 2017;18. <https://doi.org/10.1186/s12882-017-0546-1>.
- 391 [7] Akhtar MJ, Khan SA, Kumar B, Chawla P, Bhatia R, Singh K. Role of sodium dependent SLC13
392 transporter inhibitors in various metabolic disorders. *Mol Cell Biochem* 2023;478.
393 <https://doi.org/10.1007/s11010-022-04618-7>.
- 394 [8] Willmes DM, Kurzbach A, Henke C, Schumann T, Zahn G, Heifetz A, et al. The longevity gene
395 INDY (I'm Not Dead Yet) in metabolic control: Potential as pharmacological target. *Pharmacol*
396 *Ther* 2018;185. <https://doi.org/10.1016/j.pharmthera.2017.10.003>.
- 397 [9] Schumann T, König J, Henke C, Willmes DM, Bornstein SR, Jordan J, et al. Solute carrier
398 transporters as potential targets for the treatment of metabolic disease. *Pharmacol Rev*
399 2020;72. <https://doi.org/10.1124/pr.118.015735>.
- 400 [10] Birkenfeld AL, Lee HY, Guebre-Egziabher F, Alves TC, Jurczak MJ, Jornayvaz FR, et al. Deletion
401 of the mammalian INDY homolog mimics aspects of dietary restriction and protects against
402 adiposity and insulin resistance in mice. *Cell Metab* 2011;14.
403 <https://doi.org/10.1016/j.cmet.2011.06.009>.
- 404 [11] von Loeffelholz C, Lieske S, Neuschäfer-Rube F, Willmes DM, Raschzok N, Sauer IM, et al. The
405 human longevity gene homolog INDY and interleukin-6 interact in hepatic lipid metabolism.
406 *Hepatology* 2017;66. <https://doi.org/10.1002/hep.29089>.
- 407 [12] Zahn G, Willmes DM, El-Agroudy NN, Yarnold C, Jarjes-Pike R, Schaertl S, et al. A Novel and
408 Cross-Species Active Mammalian INDY (NaCT) Inhibitor Ameliorates Hepatic Steatosis in Mice
409 with Diet-Induced Obesity. *Metabolites* 2022;12. <https://doi.org/10.3390/metabo12080732>.

- 410 [13] Huard K, Brown J, Jones JC, Cabral S, Futatsugi K, Gorgoglione M, et al. Discovery and
411 characterization of novel inhibitors of the sodium-coupled citrate transporter (NaCT or
412 SLC13A5). *Sci Rep* 2015;5. <https://doi.org/10.1038/srep17391>.
- 413 [14] Kopel JJ, Bhutia YD, Sivaprakasam S, Ganapathy V. Consequences of NaCT/SLC13A5/mINDY
414 deficiency: Good versus evil, separated only by the blood-brain barrier. *Biochemical Journal*
415 2021;478. <https://doi.org/10.1042/BCJ20200877>.
- 416 [15] Gopal E, Babu E, Ramachandran S, Bhutia YD, Prasad PD, Ganapathy V. Species-specific
417 influence of lithium on the activity of SLC13A5 (NACT): Lithium-induced activation is specific
418 for the transporter in primates. *Journal of Pharmacology and Experimental Therapeutics*
419 2015;353. <https://doi.org/10.1124/jpet.114.221523>.
- 420 [16] Inoue K, Zhuang L, Ganapathy V. Human Na⁺-coupled citrate transporter: Primary structure,
421 genomic organization, and transport function. *Biochem Biophys Res Commun* 2002;299.
422 [https://doi.org/10.1016/S0006-291X\(02\)02669-4](https://doi.org/10.1016/S0006-291X(02)02669-4).
- 423 [17] Hingorani AD, Kuan V, Finan C, Kruger FA, Gaulton A, Chopade S, et al. Improving the odds of
424 drug development success through human genomics: modelling study. *Sci Rep* 2019;9.
425 <https://doi.org/10.1038/s41598-019-54849-w>.
- 426 [18] Gill D, Georgakis MK, Walker VM, Schmidt AF, Gkatzionis A, Freitag DF, et al. Mendelian
427 randomization for studying the effects of perturbing drug targets. *Wellcome Open Res* 2021;6.
428 <https://doi.org/10.12688/wellcomeopenres.16544.2>.
- 429 [19] Burgess S, Mason AM, Grant AJ, Slob EAW, Gkatzionis A, Zuber V, et al. Using genetic
430 association data to guide drug discovery and development: Review of methods and
431 applications. *Am J Hum Genet* 2023;110. <https://doi.org/10.1016/j.ajhg.2022.12.017>.
- 432 [20] Pesta DH, Perry RJ, Guebre-Egziabher F, Zhang D, Jurczak M, Fischer-Rosinsky A, et al.
433 Prevention of diet-induced hepatic steatosis and hepatic insulin resistance by second
434 generation antisense oligonucleotides targeted to the longevity gene mIndy (Slc13a5). *Aging*
435 2015;7. <https://doi.org/10.18632/aging.100854>.
- 436 [21] Brachs S, Winkel AF, Tang H, Birkenfeld AL, Brunner B, Jahn-Hofmann K, et al. Inhibition of
437 citrate cotransporter Slc13a5/mINDY by RNAi improves hepatic insulin sensitivity and
438 prevents diet-induced non-alcoholic fatty liver disease in mice. *Mol Metab* 2016;5.
439 <https://doi.org/10.1016/j.molmet.2016.08.004>.
- 440 [22] Brown TL, Nye KL, Porter BE. Growth and overall health of patients with slc13a5 citrate
441 transporter disorder. *Metabolites* 2021;11. <https://doi.org/10.3390/metabo11110746>.
- 442 [23] Bainbridge MN, Cooney E, Miller M, Kennedy AD, Wulff JE, Donti T, et al. Analyses of SLC13A5-
443 epilepsy patients reveal perturbations of TCA cycle. *Mol Genet Metab* 2017;121.
444 <https://doi.org/10.1016/j.ymgme.2017.06.009>.
- 445 [24] Dirckx N, Zhang Q, Chu EY, Tower RJ, Li Z, Guo S, et al. A specialized metabolic pathway
446 partitions citrate in hydroxyapatite to impact mineralization of bones and teeth. *Proc Natl*
447 *Acad Sci U S A* 2022;119. <https://doi.org/10.1073/pnas.2212178119>.
- 448 [25] Li Z, Wang H. Molecular mechanisms of the SLC13A5 gene transcription. *Metabolites* 2021;11.
449 <https://doi.org/10.3390/metabo11100706>.

- 450 [26] Denny JC, Ritchie MD, Basford MA, Pulley JM, Bastarache L, Brown-Gentry K, et al. PheWAS:
451 Demonstrating the feasibility of a phenome-wide scan to discover gene-disease associations.
452 *Bioinformatics* 2010;26. <https://doi.org/10.1093/bioinformatics/btq126>.
- 453 [27] Li B, Martin EB. An approximation to the F distribution using the chi-square distribution.
454 *Comput Stat Data Anal* 2002;40. [https://doi.org/10.1016/S0167-9473\(01\)00097-4](https://doi.org/10.1016/S0167-9473(01)00097-4).
- 455 [28] Elsworth B, Lyon M, Alexander T, Liu Y, Matthews P, Hallett J, et al. The MRC IEU OpenGWAS
456 data infrastructure. *BioRxiv* 2020.
- 457 [29] Neale Lab. GWAS of UK Biobank biomarker measurements 2023.
- 458 [30] Stanzick KJ, Li Y, Schlosser P, Gorski M, Wuttke M, Thomas LF, et al. Discovery and
459 prioritization of variants and genes for kidney function in >1.2 million individuals. *Nat*
460 *Commun* 2021;12. <https://doi.org/10.1038/s41467-021-24491-0>.
- 461 [31] Teumer A, Li Y, Ghasemi S, Prins BP, Wuttke M, Hermle T, et al. Genome-wide association
462 meta-analyses and fine-mapping elucidate pathways influencing albuminuria. *Nat Commun*
463 2019;10. <https://doi.org/10.1038/s41467-019-11576-0>.
- 464 [32] Wuttke M, Li Y, Li M, Sieber KB, Feitosa MF, Gorski M, et al. A catalog of genetic loci associated
465 with kidney function from analyses of a million individuals. *Nat Genet* 2019;51.
466 <https://doi.org/10.1038/s41588-019-0407-x>.
- 467 [33] Schlosser P, Scherer N, Grundner-Culemann F, Monteiro-Martins S, Haug S, Steinbrenner I, et
468 al. Genetic studies of paired metabolomes reveal enzymatic and transport processes at the
469 interface of plasma and urine. *Nat Genet* 2023;55. [https://doi.org/10.1038/s41588-023-](https://doi.org/10.1038/s41588-023-01409-8)
470 [01409-8](https://doi.org/10.1038/s41588-023-01409-8).
- 471 [34] Graham SE, Clarke SL, Wu KHH, Kanoni S, Zajac GJM, Ramdas S, et al. The power of genetic
472 diversity in genome-wide association studies of lipids. *Nature* 2021;600.
473 <https://doi.org/10.1038/s41586-021-04064-3>.
- 474 [35] Chen J, Spracklen CN, Marenne G, Varshney A, Corbin LJ, Luan J, et al. The trans-ancestral
475 genomic architecture of glycemc traits. *Nat Genet* 2021;53. [https://doi.org/10.1038/s41588-](https://doi.org/10.1038/s41588-021-00852-9)
476 [021-00852-9](https://doi.org/10.1038/s41588-021-00852-9).
- 477 [36] Haas ME, Pirruccello JP, Friedman SN, Wang M, Emdin CA, Ajmera VH, et al. Machine learning
478 enables new insights into genetic contributions to liver fat accumulation. *Cell Genomics*
479 2021;1. <https://doi.org/10.1016/j.xgen.2021.100066>.
- 480 [37] Ferkingstad E, Sulem P, Atlason BA, Sveinbjornsson G, Magnusson MI, Styrnisdottir EL, et al.
481 Large-scale integration of the plasma proteome with genetics and disease. *Nat Genet*
482 2021;53. <https://doi.org/10.1038/s41588-021-00978-w>.
- 483 [38] Said S, Pazoki R, Karhunen V, Vösa U, Ligthart S, Bodinier B, et al. Genetic analysis of over half
484 a million people characterises C-reactive protein loci. *Nat Commun* 2022;13.
485 <https://doi.org/10.1038/s41467-022-29650-5>.
- 486 [39] Burgess S, Butterworth A, Thompson SG. Mendelian randomization analysis with multiple
487 genetic variants using summarized data. *Genet Epidemiol* 2013;37:658–65.
488 <https://doi.org/10.1002/gepi.21758>.

- 489 [40] Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid instruments:
490 effect estimation and bias detection through Egger regression. *Int J Epidemiol* 2015;44:512–
491 25. <https://doi.org/10.1093/ije/dyv080>.
- 492 [41] Bowden J, Davey Smith G, Haycock PC, Burgess S. Consistent Estimation in Mendelian
493 Randomization with Some Invalid Instruments Using a Weighted Median Estimator. *Genet
494 Epidemiol* 2016;40:304–14. <https://doi.org/10.1002/gepi.21965>.
- 495 [42] Greco M F Del, Minelli C, Sheehan NA, Thompson JR. Detecting pleiotropy in Mendelian
496 randomisation studies with summary data and a continuous outcome. *Stat Med* 2015;34.
497 <https://doi.org/10.1002/sim.6522>.
- 498 [43] Yavorska OO, Burgess S. MendelianRandomization: An R package for performing Mendelian
499 randomization analyses using summarized data. *Int J Epidemiol* 2017;46.
500 <https://doi.org/10.1093/ije/dyx034>.
- 501 [44] Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J, et al. UK Biobank: An Open Access
502 Resource for Identifying the Causes of a Wide Range of Complex Diseases of Middle and Old
503 Age. *PLoS Med* 2015;12. <https://doi.org/10.1371/journal.pmed.1001779>.
- 504 [45] Bycroft C, Freeman C, Petkova D, Band G, Elliott LT, Sharp K, et al. The UK Biobank resource
505 with deep phenotyping and genomic data. *Nature* 2018;562. [https://doi.org/10.1038/s41586-
506 018-0579-z](https://doi.org/10.1038/s41586-018-0579-z).
- 507 [46] Wu P, Gifford A, Meng X, Li X, Campbell H, Varley T, et al. Mapping ICD-10 and ICD-10-CM
508 Codes to phecodes: Workflow development and initial evaluation. *JMIR Med Inform* 2019;7.
509 <https://doi.org/10.2196/14325>.
- 510 [47] Carroll RJ, Bastarache L, Denny JC. R PheWAS: Data analysis and plotting tools for phenome-
511 wide association studies in the R environment. *Bioinformatics* 2014;30.
512 <https://doi.org/10.1093/bioinformatics/btu197>.
- 513 [48] Skrivankova VW, Richmond RC, Woolf BAR, Yarmolinsky J, Davies NM, Swanson SA, et al.
514 Strengthening the Reporting of Observational Studies in Epidemiology Using Mendelian
515 Randomization: The STROBE-MR Statement. *JAMA - Journal of the American Medical
516 Association* 2021;326. <https://doi.org/10.1001/jama.2021.18236>.
- 517 [49] Lopez-Giacoman S. Biomarkers in chronic kidney disease, from kidney function to kidney
518 damage. *World J Nephrol* 2015;4. <https://doi.org/10.5527/wjn.v4.i1.57>.
- 519 [50] Matovinović MS. 1. Pathophysiology and Classification of Kidney Diseases. *EJIFCC* 2009;20.
- 520 [51] Thevenon J, Milh M, Feillet F, St-Onge J, Duffourd Y, Jugé C, et al. Mutations in SLC13A5 cause
521 autosomal-recessive epileptic encephalopathy with seizure onset in the first days of Life. *Am J
522 Hum Genet* 2014;95. <https://doi.org/10.1016/j.ajhg.2014.06.006>.
- 523 [52] Rocha DR, Xue L, Gomes Sousa HM, Carvalho Matos AC, Hoorn EJ, Salih M, et al. Urinary
524 Citrate Is Associated with Kidney Outcomes in Early Polycystic Kidney Disease. *Kidney360*
525 2022;3. <https://doi.org/10.34067/KID.0004772022>.
- 526 [53] Tanner GA, Tanner JA. Citrate therapy for polycystic kidney disease in rats. *Kidney Int* 2000;58.
527 <https://doi.org/10.1111/j.1523-1755.2000.00357.x>.

- 528 [54] Posada-Ayala M, Zubiri I, Martin-Lorenzo M, Sanz-Maroto A, Molero D, Gonzalez-Calero L, et
529 al. Identification of a urine metabolomic signature in patients with advanced-stage chronic
530 kidney disease. *Kidney Int* 2014;85. <https://doi.org/10.1038/ki.2013.328>.
- 531 [55] Hallan S, Afkarian M, Zelnick LR, Kestenbaum B, Sharma S, Saito R, et al. Metabolomics and
532 Gene Expression Analysis Reveal Down-regulation of the Citric Acid (TCA) Cycle in Non-
533 diabetic CKD Patients. *EBioMedicine* 2017;26. <https://doi.org/10.1016/j.ebiom.2017.10.027>.
- 534 [56] Liu JJ, Liu S, Gurung RL, Ching J, Kovalik JP, Tan TY, et al. Urine tricarboxylic acid cycle
535 metabolites predict progressive chronic kidney disease in type 2 diabetes. *Journal of Clinical
536 Endocrinology and Metabolism* 2018;103. <https://doi.org/10.1210/jc.2018-00947>.
- 537 [57] Goraya N, Simoni J, Sager LN, Mamun A, Madias NE, Wesson DE. Urine citrate excretion
538 identifies changes in acid retention as eGFR declines in patients with chronic kidney disease.
539 *Am J Physiol Renal Physiol* 2019;317. <https://doi.org/10.1152/ajprenal.00044.2019>.
- 540 [58] Mutter S, Valo E, Aittomäki V, Nybo K, Raivonen L, Thorn LM, et al. Urinary metabolite
541 profiling and risk of progression of diabetic nephropathy in 2670 individuals with type 1
542 diabetes. *Diabetologia* 2022;65. <https://doi.org/10.1007/s00125-021-05584-3>.
- 543 [59] Domrongkitchaiporn S, Stitchantrakul W, Kochakarn W. Causes of Hypocitraturia in Recurrent
544 Calcium Stone Formers: Focusing on Urinary Potassium Excretion. *American Journal of Kidney
545 Diseases* 2006;48. <https://doi.org/10.1053/j.ajkd.2006.06.008>.
- 546 [60] Willmes DM, Daniels M, Kurzbach A, Lieske S, Bechmann N, Schumann T, et al. The longevity
547 gene mIndy (I'm Not Dead, Yet) affects blood pressure through sympathoadrenal
548 mechanisms. *JCI Insight* 2021;6. <https://doi.org/10.1172/jci.insight.136083>.
- 549 [61] Burgess S, Butterworth A, Malarstig A, Thompson SG. Use of Mendelian randomisation to
550 assess potential benefit of clinical intervention. *BMJ* 2012;345.
551 <https://doi.org/10.1136/bmj.e7325>.
- 552 [62] Burgess S. Sample size and power calculations in Mendelian randomization with a single
553 instrumental variable and a binary outcome. *Int J Epidemiol* 2014;43.
554 <https://doi.org/10.1093/ije/dyu005>.
- 555 [63] Neuschäfer-Rube F, Schraplau A, Schewe B, Lieske S, Krützfeldt JM, Ringel S, et al.
556 Arylhydrocarbon receptor-dependent mIndy (Slc13a5) induction as possible contributor to
557 benzo[a]pyrene-induced lipid accumulation in hepatocytes. *Toxicology* 2015;337.
558 <https://doi.org/10.1016/j.tox.2015.08.007>.
- 559 [64] Li L, Li H, Garzel B, Yang H, Sueyoshi T, Li Q, et al. SLC13A5 Is a novel transcriptional target of
560 the pregnane x receptor and sensitizes drug-induced steatosis in human liver. *Mol Pharmacol*
561 2015;87. <https://doi.org/10.1124/mol.114.097287>.
- 562 [65] Paternoster L, Tilling K, Davey Smith G. Genetic epidemiology and Mendelian randomization
563 for informing disease therapeutics: Conceptual and methodological challenges. *PLoS Genet*
564 2017;13. <https://doi.org/10.1371/journal.pgen.1006944>.
- 565 [66] Mitchell RE, Hartley AE, Walker VM, Gkatzionis A, Yarmolinsky J, Bell JA, et al. Strategies to
566 investigate and mitigate collider bias in genetic and Mendelian randomisation studies of
567 disease progression. *PLoS Genet* 2023;19. <https://doi.org/10.1371/journal.pgen.1010596>.

568 [67] Cai S, Allen RJ, Wain LV, Dudbridge F. Reassessing the association of MUC5B with survival in
569 idiopathic pulmonary fibrosis. *Ann Hum Genet* 2023;87:248–53.
570 <https://doi.org/https://doi.org/10.1111/ahg.12522>.

571

572 **Acknowledgements**

573 ***Funding***

574 This work was supported by Eternygen GmbH. Dipender Gill acknowledges support by the British
575 Heart Foundation Centre of Research Excellence at Imperial College London (RE/18/4/34215).
576 Stephen Burgess is supported by the Wellcome Trust (225790/Z/22/Z) and the United Kingdom
577 Research and Innovation Medical Research Council (MC_UU_00002/7).

578

579 ***Conflicts of interest***

580 Dipender Gill and Rubinder Gill are employed part-time by Primula Group. Stephen Burgess has
581 received personal fees from Primula Group. Andreas Birkenfeld and Jens Jordan are minor
582 shareholders of Eternygen GmbH, and Grit Zahn is minor shareholder and employee of Eternygen
583 GmbH. Andreas Birkenfeld has received research funding from Boehringer Ingelheim und
584 AstraZeneca.

585 **Table and Figure**

586 Table 1. Genome-wide association study summary data used for the Mendelian randomization
587 analyses.

Category	Trait	Unit	Population	Sample size	Citation
Biomarker	Plasma citrate	SD	European ancestry UK Biobank participants	115,064	[28]
	Plasma calcium	SD	British ancestry UK Biobank participants	361,194	[29]
Renal	Creatinine-eGFR	SD of log	Multi-ancestry GWAS meta-analysis	1,201,929	[30]
	Cystatin C-eGFR	SD of log			
	Blood urea nitrogen	SD of log			
	Urine albumin-creatinine ratio	SD of log	Multi-ancestry GWAS meta-analysis	564,257	[31]
	Chronic kidney disease	Log OR	Multi-ancestry GWAS meta-analysis	625,219 (64,164 cases)	[32]
	Microalbuminuria	Log OR	Multi-ancestry GWAS meta-analysis	348,954 (51,861 cases)	[31]
Metabolome	1,296 plasma metabolites	SD	German Chronic Kidney Disease study	5,023	[33]
	1,399 urine metabolites	SD			
Lipid, glucose and inflammation	Plasma low-density lipoprotein cholesterol	SD	European ancestry GWAS meta-analysis	1,320,016	[34]
	Plasma high-density lipoprotein cholesterol	SD			
	Plasma triglycerides	SD			
	Fasting plasma glucose	mmol/l	European ancestry GWAS meta-analysis	200,622	[35]
	Imaging-derived liver fat (MRI-PDFF)	SD	UK Biobank participants	36,703	[36]
	Plasma interleukin 6 binding aptamer level	SD	deCODE Icelandic study	35,559	[37]
	Plasma C-reactive protein level	SD of log	European ancestry GWAS	427,367	[38]
Proteome	4,907 plasma protein-binding aptamers	SD	deCODE Icelandic study	35,559	[37]

588 The full list of analysed metabolites and protein-binding aptamers are available in the Supplementary files. Full
589 study details and access to GWAS summary data are provided in the original publications. BUN: blood urea
590 nitrogen; eGFR: estimated glomerular filtration rate; GWAS: genome-wide association study; MRI-PDFF:
591 magnetic resonance imaging derived proton density fat fraction; OR: odds ratio; SD: standard deviation; uACR:
592 urine albumin-creatinine ratio.


593 Figure 1. Overview of the study design.

	SLC13A5 inhibition Identify genetic instruments for SLC13A5 inhibition <small>SNPs within 200kb of the SLC13A5 gene, uncorrelated ($r^2 < 0.1$) and associated with plasma citrate at $p < 5 \times 10^{-8}$</small>	Higher plasma citrate Identify genetic instruments for plasma citrate <small>SNPs from throughout the genome, uncorrelated ($r^2 < 0.1$) and associated with plasma citrate at $p < 5 \times 10^{-8}$</small>	Mendelian randomization sensitivity analyses
	Confirm instrument validity by performing Mendelian randomization to investigate effects on plasma calcium		
Primary analysis	Hypothesis-driven Mendelian randomization analysis investigating effects on parameters of renal function <small>Creatinine-eGFR, cystatin C-eGFR, BUN, uACR, risk of CKD and microalbuminuria</small>		
Exploratory analyses	Exploratory Mendelian randomization analyses investigating effects of SLC13A5 inhibition on: <ol style="list-style-type: none"> 1. Plasma and urine metabolites <small>1,296 plasma metabolites and 1,399 urine metabolites</small> 2. Biomarkers of glucose and lipid metabolism, and inflammation <small>Glucose, HDLc, LDLc and triglycerides, liver fat, IL6, CRP</small> 3. Plasma proteins <small>4,907 plasma protein-binding aptamers</small> Phenome-wide association study <small>988 clinical outcomes</small>	Repeat all analyses, but considering plasma citrate as the exposure, instead of SLC13A5 inhibition	Egger and weighted median statistical sensitivity analyses

594

595 BUN: blood urea nitrogen, CRP:C-reactive protein, CKD: chronic kidney disease; eGFR: estimated glomerular
 596 filtration rate, HDLc: high-density lipoprotein cholesterol, IL6: interleukin 6; LDLc: low-density lipoprotein
 597 cholesterol, SNP: single-nucleotide polymorphism, uACR: urine albumin-creatinine ratio.


598 Figure 2. Mendelian randomization estimates for the association of genetically proxied SLC13A5
599 inhibition with kidney traits.



600

601 Mendelian randomization estimates are scaled per 1-standard deviation (SD) increase in plasma citrate through
602 genetically proxied SLC13A5 inhibition. The units for the BUN, creatinine-eGFR, cystatin C-eGFR and uACR are
603 SD change in log transformed levels. The units for CKD and microalbuminuria are log odds ratio. Raw p values
604 are presented. BUN: blood urea nitrogen, chronic kidney disease; eGFR: estimated glomerular filtration rate,
605 urine albumin-creatinine ratio.

606 Figure 3. Mendelian randomization estimates for the association of genetically proxied SLC13A5
607 inhibition with biomarkers of glucose and lipid metabolism, and inflammation.



608

609 Mendelian randomization estimates are scaled per 1-standard deviation (SD) increase in plasma citrate through
610 genetically proxied SLC13A5 inhibition. The units for fasting glucose is mmol/l, the units for C-reactive protein
611 (CRP) is standard deviation (SD) change of log transformed levels, and the remaining exposures are measured
612 in SD units. HDLc: high-density lipoprotein cholesterol, IL6: interleukin 6, LDLc: low-density lipoprotein
613 cholesterol.

614

615 **Supplementary files**

- 616 Supplementary checklist. Strengthening the Reporting of Observational Studies in Epidemiology
617 using Mendelian Randomization checklist.
- 618 Supplementary Table 1. Single-nucleotide polymorphisms used as instruments for SLC13A5
619 inhibition. Genetic associations with plasma citrate are presented for variants within 200kB of the
620 *SLC13A5* gene. SNP: single-nucleotide polymorphism.
- 621 Supplementary Table 2. Metabolome-wide Mendelian randomization analysis investigating the
622 associations of genetically proxied SLC13A5 inhibition with plasma metabolites. CI: confidence
623 interval.
- 624 Supplementary Table 3. Metabolome-wide Mendelian randomization analysis investigating the
625 associations of genetically proxied SLC13A5 inhibition with urine metabolites. CI: confidence interval.
- 626 Supplementary Table 4. Proteome-wide Mendelian randomization analysis investigating the
627 associations of genetically proxied SLC13A5 inhibition with plasma protein-binding aptamers.
- 628 Supplementary Table 5. Phenome-wide association study investigating the associations of a
629 standardised genetic risk score for SLC13A5 inhibition with clinical outcomes across the phenome.
- 630 Supplementary Table 6. Single-nucleotide polymorphisms used as instruments for plasma citrate
631 levels, selected from throughout the genome. SNP: single-nucleotide polymorphism.
- 632 Supplementary Table 7. Metabolome-wide Mendelian randomization analysis investigating the
633 associations of genetically predicted plasma citrate levels with plasma metabolites. CI: confidence
634 interval.
- 635 Supplementary Table 8. Metabolome-wide Mendelian randomization analysis investigating the
636 associations of genetically predicted plasma citrate levels with urine metabolites. CI: confidence
637 interval.
- 638 Supplementary Table 9. Proteome-wide Mendelian randomization analysis investigating the
639 associations of genetically predicted plasma citrate levels with plasma protein-binding aptamers.
- 640 Supplementary Table 10. Phenome-wide association study investigating the associations of a
641 standardised genetic risk score for plasma citrate with clinical outcomes across the phenome.
- 642 Supplementary Table 11. Mendelian randomization statistical sensitivity analyses for biomarkers of
643 renal function, glucose and lipid metabolism, and inflammation.
- 644